JP2013518870A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518870A5 JP2013518870A5 JP2012551732A JP2012551732A JP2013518870A5 JP 2013518870 A5 JP2013518870 A5 JP 2013518870A5 JP 2012551732 A JP2012551732 A JP 2012551732A JP 2012551732 A JP2012551732 A JP 2012551732A JP 2013518870 A5 JP2013518870 A5 JP 2013518870A5
- Authority
- JP
- Japan
- Prior art keywords
- total weight
- pellets
- sustained release
- layer
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008188 pellet Substances 0.000 claims 27
- 239000010410 layer Substances 0.000 claims 18
- 229920000642 polymer Polymers 0.000 claims 18
- 238000013268 sustained release Methods 0.000 claims 18
- 239000012730 sustained-release form Substances 0.000 claims 18
- 239000013543 active substance Substances 0.000 claims 12
- 239000011247 coating layer Substances 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 11
- 229940079593 drug Drugs 0.000 claims 11
- 239000000314 lubricant Substances 0.000 claims 11
- 238000013265 extended release Methods 0.000 claims 9
- RUOKEQAAGRXIBM-UHFFFAOYSA-N n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2C(NCC#C)CCC2=C1 RUOKEQAAGRXIBM-UHFFFAOYSA-N 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 7
- 239000011230 binding agent Substances 0.000 claims 7
- 239000003826 tablet Substances 0.000 claims 7
- 239000011248 coating agent Substances 0.000 claims 6
- 238000000576 coating method Methods 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 238000009498 subcoating Methods 0.000 claims 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 5
- 229920001223 polyethylene glycol Polymers 0.000 claims 5
- 239000000454 talc Substances 0.000 claims 5
- 229910052623 talc Inorganic materials 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 239000011148 porous material Substances 0.000 claims 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 238000002955 isolation Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- 239000001856 Ethyl cellulose Substances 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 229920001688 coating polymer Polymers 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 claims 2
- 239000002702 enteric coating Substances 0.000 claims 2
- 238000009505 enteric coating Methods 0.000 claims 2
- 229920001249 ethyl cellulose Polymers 0.000 claims 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 2
- 239000004014 plasticizer Substances 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical group CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims 1
- 241000255925 Diptera Species 0.000 claims 1
- 229920003153 Eudragit® NE polymer Polymers 0.000 claims 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 claims 1
- 229920003152 Eudragit® RS polymer Polymers 0.000 claims 1
- 229920003137 Eudragit® S polymer Polymers 0.000 claims 1
- 229920003134 Eudragit® polymer Polymers 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- -1 Kollicoat® Polymers 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 208000001738 Nervous System Trauma Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical class CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 1
- 239000000783 alginic acid Substances 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 229960001126 alginic acid Drugs 0.000 claims 1
- 150000004781 alginic acids Chemical class 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 229920002988 biodegradable polymer Polymers 0.000 claims 1
- 239000004621 biodegradable polymer Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 239000007910 chewable tablet Substances 0.000 claims 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000010828 elution Methods 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 claims 1
- 229940075507 glyceryl monostearate Drugs 0.000 claims 1
- 239000001087 glyceryl triacetate Substances 0.000 claims 1
- 235000013773 glyceryl triacetate Nutrition 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- JDBJJCWRXSVHOQ-UHFFFAOYSA-N methanesulfonic acid;n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine Chemical compound CS(O)(=O)=O.C1=CC=C2C(NCC#C)CCC2=C1 JDBJJCWRXSVHOQ-UHFFFAOYSA-N 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 208000028412 nervous system injury Diseases 0.000 claims 1
- 235000021317 phosphate Nutrition 0.000 claims 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 229920002643 polyglutamic acid Polymers 0.000 claims 1
- 229920002959 polymer blend Polymers 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000000541 pulsatile effect Effects 0.000 claims 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 claims 1
- 229960000245 rasagiline Drugs 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 1
- 229940033134 talc Drugs 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 229960002622 triacetin Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30101910P | 2010-02-03 | 2010-02-03 | |
| US61/301,019 | 2010-02-03 | ||
| PCT/IL2011/000126 WO2011095973A1 (en) | 2010-02-03 | 2011-02-03 | Extended release formulations of rasagiline and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016186945A Division JP6440662B2 (ja) | 2010-02-03 | 2016-09-26 | ラサギリンの持続放出性製剤およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013518870A JP2013518870A (ja) | 2013-05-23 |
| JP2013518870A5 true JP2013518870A5 (enExample) | 2014-03-20 |
| JP6045347B2 JP6045347B2 (ja) | 2016-12-14 |
Family
ID=43896855
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012551732A Active JP6045347B2 (ja) | 2010-02-03 | 2011-02-03 | ラサギリンの持続放出性製剤およびその使用 |
| JP2016186945A Active JP6440662B2 (ja) | 2010-02-03 | 2016-09-26 | ラサギリンの持続放出性製剤およびその使用 |
| JP2018216973A Active JP6770564B2 (ja) | 2010-02-03 | 2018-11-20 | ラサギリンの持続放出性製剤およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016186945A Active JP6440662B2 (ja) | 2010-02-03 | 2016-09-26 | ラサギリンの持続放出性製剤およびその使用 |
| JP2018216973A Active JP6770564B2 (ja) | 2010-02-03 | 2018-11-20 | ラサギリンの持続放出性製剤およびその使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9943489B2 (enExample) |
| EP (2) | EP2531181B1 (enExample) |
| JP (3) | JP6045347B2 (enExample) |
| KR (1) | KR101791715B1 (enExample) |
| CN (1) | CN102791258B (enExample) |
| AU (1) | AU2011212068B2 (enExample) |
| BR (1) | BR112012019374B1 (enExample) |
| CA (1) | CA2789006C (enExample) |
| CL (1) | CL2012002175A1 (enExample) |
| CY (1) | CY1121781T1 (enExample) |
| DK (1) | DK2531181T3 (enExample) |
| ES (1) | ES2733133T3 (enExample) |
| HU (1) | HUE044221T2 (enExample) |
| IL (1) | IL221274A (enExample) |
| LT (1) | LT2531181T (enExample) |
| MX (1) | MX354423B (enExample) |
| NZ (1) | NZ602111A (enExample) |
| PL (1) | PL2531181T3 (enExample) |
| PT (1) | PT2531181T (enExample) |
| RS (1) | RS58988B1 (enExample) |
| RU (2) | RU2607595C2 (enExample) |
| SG (1) | SG183150A1 (enExample) |
| TR (1) | TR201909277T4 (enExample) |
| WO (1) | WO2011095973A1 (enExample) |
| ZA (1) | ZA201206462B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2789006C (en) * | 2010-02-03 | 2018-11-27 | Pharma Two B Ltd. | Extended release formulations of rasagiline and uses thereof |
| CA2758556A1 (en) * | 2011-11-17 | 2013-05-17 | Pharmascience Inc. | Pharmaceutical composition of amphetamine mixed salts |
| US9504657B2 (en) * | 2012-01-12 | 2016-11-29 | Pharmatwob Ltd. | Fixed dose combination therapy of Parkinson's disease |
| JP6243351B2 (ja) | 2012-01-12 | 2017-12-06 | ファーマ ツゥ ビー リミテッド | パーキンソン病の固定投与量薬剤組合せ治療 |
| US9457008B2 (en) | 2012-03-23 | 2016-10-04 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China | Joint product comprising synephrine and topiramate |
| CN102579367B (zh) * | 2012-03-23 | 2014-03-12 | 中国人民解放军军事医学科学院毒物药物研究所 | 托吡酯缓释药物组合物、其制备方法及用途 |
| CN103316026B (zh) | 2012-03-23 | 2016-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 含芬特明和托吡酯的联合产品及其制备方法 |
| WO2014028868A1 (en) * | 2012-08-17 | 2014-02-20 | Teva Pharmaceutical Industries Ltd. | Parenteral formulation of rasagiline |
| IN2013MU01782A (enExample) * | 2013-05-20 | 2015-06-26 | Cadila Healthcare Ltd | |
| US20150275167A1 (en) * | 2014-03-28 | 2015-10-01 | Corning Incorporated | Composition and method for cell culture sustained release |
| US10709700B2 (en) * | 2014-09-15 | 2020-07-14 | Orphazyme A/S | Arimoclomol formulation |
| CA3064006C (en) * | 2017-05-19 | 2025-09-16 | Biscayne Neurotherapeutics Inc | Modified release pharmaceutical compositions of huperzine and methods of using the same |
| CN107049985B (zh) * | 2017-06-07 | 2020-06-19 | 广州帝奇医药技术有限公司 | 一种抗帕金森病药物的长效缓释制剂及其制备方法 |
| KR20210005662A (ko) * | 2018-04-25 | 2021-01-14 | 뉴로센트리아, 인크. | 마그네슘 트레오네이트 조성물 및 이의 용도 |
| KR20220015437A (ko) * | 2019-05-31 | 2022-02-08 | 데날리 테라퓨틱스 인크. | 피리미디닐아미노-피라졸 화합물의 변형 방출 제제, 및 치료 방법 |
| KR20210014289A (ko) | 2019-07-30 | 2021-02-09 | (주)비씨월드제약 | 라사길린을 함유하는 서방출성 미립구의 제조방법 |
| AR121619A1 (es) * | 2020-03-25 | 2022-06-22 | Inibsa Ginecologia S A | Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación |
| EP4337176B1 (en) * | 2021-05-11 | 2025-07-16 | Advicenne | Prolonged-release pharmaceutical composition for oral administration of sultiame |
| CN118680910B (zh) * | 2024-08-26 | 2024-12-03 | 山东齐都药业有限公司 | 用于缓释递送雷沙吉兰甲磺酸盐的药物组合物及其制备方法和应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4415547A (en) * | 1982-06-14 | 1983-11-15 | Sterling Drug Inc. | Sustained-release pharmaceutical tablet and process for preparation thereof |
| US4861800A (en) | 1987-08-18 | 1989-08-29 | Buyske Donald A | Method for administering the drug deprenyl so as to minimize the danger of side effects |
| HU208484B (en) | 1988-08-17 | 1993-11-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia |
| US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| IL92952A (en) | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| US5192808A (en) | 1990-08-31 | 1993-03-09 | Deprenyl Animal Health, Inc. | Therapeutic effect of L-deprenyl in the management of pituitary-dependent hyperadrenocorticism (cushing's disease) |
| US5151449A (en) | 1990-08-31 | 1992-09-29 | Deprenyl Animal Health, Inc. | Use of L-deprenyl for retention of specific physiological functions |
| CA2039194C (en) | 1990-08-31 | 1997-01-28 | Norton W. Milgram | Uses of l-deprenyl and compositions for same |
| US5225446A (en) | 1990-08-31 | 1993-07-06 | Deprenyl Animal Health, Inc. | Use of 1-deprenyl for retention of specific physiological functions |
| US5169868A (en) | 1991-03-01 | 1992-12-08 | University Of Saskatchewan | Aliphatic propargylamines as specific mao-b inhibitors |
| AU1450592A (en) | 1991-04-04 | 1992-11-02 | University Of Toronto Innovations Foundation, The | Use of deprenyl to maintain, prevent loss, or recover nerve cell function |
| WO1992021333A2 (en) | 1991-05-24 | 1992-12-10 | Pharmavene, Inc. | Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors |
| IL99759A (en) | 1991-10-16 | 1997-06-10 | Teva Pharma | Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them |
| US5242950A (en) | 1992-04-23 | 1993-09-07 | Somerset Pharmaceuticals, Inc. | Treatment of macular degeneration |
| JP2916978B2 (ja) * | 1993-08-25 | 1999-07-05 | エスエス製薬株式会社 | 放出開始制御型製剤 |
| IL111240A (en) * | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
| US6348208B1 (en) | 1995-01-13 | 2002-02-19 | Somerset Pharmaceuticals, Inc. | Methods and pharmaceutical compositions employing desmethylselegiline |
| PE57198A1 (es) * | 1996-03-25 | 1998-10-10 | American Home Prod | Formula de liberacion prolongada |
| IL118836A (en) | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
| US6251938B1 (en) | 1996-12-18 | 2001-06-26 | Teva Pharmaceutical Industries, Ltd., | Phenylethylamine derivatives |
| ES2241064T3 (es) | 1996-12-18 | 2005-10-16 | Teva Pharmaceutical Industries, Ltd. | Derivados de aminoindano. |
| US5840979A (en) | 1997-07-14 | 1998-11-24 | University Of Saskatchewan | Aliphatic propargylamines as cellular rescue agents |
| KR20020008167A (ko) | 1999-04-29 | 2002-01-29 | 플레믹 크리스티안 | 잠재적 항정신병제로서의 글리신 분해계 저해제 |
| CA2452738C (en) * | 2001-07-04 | 2011-06-14 | Sun Pharmaceutical Industries Limited | Gastric retention controlled drug delivery system |
| US20040076668A1 (en) | 2002-07-03 | 2004-04-22 | Pfizer Inc. | Controlled-release pharmaceutical formulations |
| ES2588780T3 (es) * | 2002-11-15 | 2016-11-04 | Teva Pharmaceutical Industries Limited | Uso de rasagilina con o sin riluzol para el tratamiento de la esclerosis lateral amiotrófica |
| CA2554959A1 (en) * | 2004-01-29 | 2005-08-11 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions |
| CA2574925A1 (en) | 2004-07-26 | 2006-02-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical dosage forms including rasagiline |
| AR055070A1 (es) * | 2005-06-29 | 2007-08-01 | Panacea Biotec Ltd | Una composicion farmaceutica de liberacion sostenida, proceso para la preparacion de dicha composicion, metodo para la utilizacion de la misma y su uso |
| WO2007016350A2 (en) * | 2005-07-28 | 2007-02-08 | Supernus Pharmaceuticals, Inc. | Modified release tablet formulations with enhanced mechanical properties |
| US20070048371A1 (en) * | 2005-07-28 | 2007-03-01 | Shojaei Amir H | Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily |
| CN101032474B (zh) * | 2006-03-06 | 2011-02-16 | 重庆医药工业研究院有限责任公司 | 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法 |
| CN101486655A (zh) * | 2008-01-17 | 2009-07-22 | 美德（江西）生物科技有限公司 | 甲磺酸雷沙吉兰晶形及其制备方法 |
| MX2010013393A (es) | 2008-06-06 | 2011-06-21 | Pharma Two B Ltd | Composiciones farmaceuticas para el tratamiento de la enfermedad de parkinson. |
| US20100008983A1 (en) * | 2008-06-10 | 2010-01-14 | Muhammad Safadi | Rasagiline soft gelatin capsules |
| WO2010007181A2 (en) * | 2008-07-18 | 2010-01-21 | Medichem, S.A. | New salt forms of an aminoindan derivative |
| EP2218444A3 (en) * | 2009-01-23 | 2010-08-25 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
| CA2789006C (en) * | 2010-02-03 | 2018-11-27 | Pharma Two B Ltd. | Extended release formulations of rasagiline and uses thereof |
-
2011
- 2011-02-03 CA CA2789006A patent/CA2789006C/en active Active
- 2011-02-03 SG SG2012057493A patent/SG183150A1/en unknown
- 2011-02-03 AU AU2011212068A patent/AU2011212068B2/en active Active
- 2011-02-03 JP JP2012551732A patent/JP6045347B2/ja active Active
- 2011-02-03 KR KR1020127023006A patent/KR101791715B1/ko active Active
- 2011-02-03 ES ES11707489T patent/ES2733133T3/es active Active
- 2011-02-03 WO PCT/IL2011/000126 patent/WO2011095973A1/en not_active Ceased
- 2011-02-03 EP EP11707489.8A patent/EP2531181B1/en active Active
- 2011-02-03 US US13/577,099 patent/US9943489B2/en active Active
- 2011-02-03 DK DK11707489.8T patent/DK2531181T3/da active
- 2011-02-03 CN CN201180012590.4A patent/CN102791258B/zh active Active
- 2011-02-03 HU HUE11707489 patent/HUE044221T2/hu unknown
- 2011-02-03 RU RU2012136723A patent/RU2607595C2/ru active
- 2011-02-03 EP EP19159171.8A patent/EP3517103A1/en not_active Withdrawn
- 2011-02-03 TR TR2019/09277T patent/TR201909277T4/tr unknown
- 2011-02-03 LT LTEP11707489.8T patent/LT2531181T/lt unknown
- 2011-02-03 RU RU2016141314A patent/RU2734632C2/ru active
- 2011-02-03 PL PL11707489T patent/PL2531181T3/pl unknown
- 2011-02-03 MX MX2012009079A patent/MX354423B/es active IP Right Grant
- 2011-02-03 NZ NZ602111A patent/NZ602111A/en not_active IP Right Cessation
- 2011-02-03 PT PT11707489T patent/PT2531181T/pt unknown
- 2011-02-03 RS RS20190810A patent/RS58988B1/sr unknown
- 2011-02-03 BR BR112012019374-0A patent/BR112012019374B1/pt active IP Right Grant
-
2012
- 2012-08-02 IL IL221274A patent/IL221274A/en active IP Right Grant
- 2012-08-03 CL CL2012002175A patent/CL2012002175A1/es unknown
- 2012-08-28 ZA ZA2012/06462A patent/ZA201206462B/en unknown
-
2016
- 2016-09-26 JP JP2016186945A patent/JP6440662B2/ja active Active
-
2018
- 2018-11-20 JP JP2018216973A patent/JP6770564B2/ja active Active
-
2019
- 2019-07-03 CY CY20191100699T patent/CY1121781T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013518870A5 (enExample) | ||
| US8557282B2 (en) | Extended release compositions comprising as active compound venlafaxine hydrochloride | |
| RU2012136723A (ru) | Составы разагилина с пролонгированным высвобождением и их применение | |
| JP2007511510A (ja) | 持続放出性ベンラファキシン製剤 | |
| SG184388A1 (en) | Pharmaceutical formulations for the treatment of overactive bladder | |
| WO2009014532A1 (en) | Stabilized tolterodine tartrate formulations | |
| CN102970983A (zh) | 耐受酒精的口服药物制剂 | |
| HUE029680T2 (en) | Dispensing systems containing weakly basic active ingredients and organic acids | |
| US20090004284A1 (en) | Controlled release tamsulosin hydrochloride formulation | |
| JP2015500853A (ja) | 即時放出マルチユニットペレットシステム | |
| JP3645816B2 (ja) | ロラタジン及びプソイドエフェドリンを含有する医薬カプセル組成物 | |
| US20110135724A1 (en) | Ondansetron Orally Disintegrating Tablet Compositions for Prevention of Nausea and Vomiting | |
| RU2014132940A (ru) | Терапия болезни паркинсона с применением комбинации с фиксированными дозами | |
| US20080226711A1 (en) | Pharmaceutical compositions of duloxetine | |
| EP4007568A1 (en) | Pharmaceutical composition comprising dabigatran etexilate | |
| CA2645940A1 (en) | Controlled release formulation of tolterodine | |
| JP2003500348A (ja) | 多粒子状制御放出選択的セロトニン再吸収阻害剤製剤 | |
| US20090192228A1 (en) | Controlled-Release Tolterodine Compositions and Methods | |
| EP2359814A1 (en) | Pharmaceutical mini-tablets for sustained release of flecainide acetate | |
| JP2009504795A (ja) | １−（４−クロロアニリノ）−４−（４−ピリジルメチル）フタラジンおよびｐＨ調整剤を含む固体医薬組成物 | |
| US10881615B2 (en) | Pharmaceutical composition comprising dabigatran etexilate, and preparation method, solid preparation and use thereof | |
| JP6626492B2 (ja) | コハク酸メトプロロールのカプセル剤形 | |
| JP2009542669A (ja) | ピペリジノアルカノールと充血除去剤の組み合わせを含んで成る医薬組成物 | |
| US20090169618A1 (en) | Zolpidem pharmaceutical compositions | |
| KR20200078146A (ko) | 내산성이 우수한 탐수로신 염산염 함유 제약 조성물 및 이의 제조방법 |